

SUPPLEMENTAL MATERIAL

Supplemental Table 1. Antibodies used for flow cytometry

Surface marker	Color	Company
CD14	PE-Cy7	BD
CD16	APC-Cy7	BD
HLA-DR	PerCpCy5.5	BD
CD192 (CCR2)	APC	BD
CD11C	APC	BD
CD18	APC	BD

PE indicates phycoerythrin, Cy; CyChrome, APC; allophycocyanin, HLA; human leukocyte antigen, PerCP; peridinin-chlorophyll-protein.

Supplemental Table 2: Unadjusted linear regression analysis in RA subjects with TBR Max as the dependent variable

Characteristic	β (95% CI)	P value
Age	-0.322(-0.039-0.007)	0.165
BMI	0.096(0.385-0.705)	0.705
SBP	-0.064(-0.012-0.009)	0.793
Current Smoking	0.545(-0.066-0.519)	0.014

Data are standardized coefficient (β) with 95% confidence intervals (CI). BMI indicates body mass index, SBP; systolic blood pressure.

Supplemental Table 2: Clinical characteristics– *ex vivo* experiments

	Control (n=20)	RA, no anti-TNF (n=16)	RA, anti-TNF (n=20)
Sex, male/female	9/11	3/13	7/13
Age, years	56±10	53±10	54±9
Body mass index, kg/m²	26±4	25±6	26±4
Smoking, yes/no	2/20	6/16	5/20
SBP, mm Hg	131±13	125±20	139±20*
DPB, mm Hg	84±10	82±13	84±10
Total cholesterol, mmol/L	5.5±1	5.4±0.7	5.0±0.9
LDL cholesterol, mmol/L	3.4±0.9	3.3±0.7	2.7±0.9*
HDL cholesterol, mmol/L	1.6±0.5	1.7±0.4	1.8±0.6
Triglycerides, mmol/L	0.8[0.7-1.1]	0.9[0.8-1.3]	0.8[1.3]
WBC, 10E9/L	5.5±0.7	5.5±1.5	5.9±1.6
- Lymfocytes	- 1.8±0.5	- 2.8±5.1	- 2.0±0.7
- Neutrofilis	- 3.0±0.7	- 3.2±1.4	- 3.2±1.1
- Monocytes	- 0.5±0.1	- 0.5±0.2	- 0.6±0.2

*Values are n, mean ± SD or median [IQR,] for skewed data. SBP indicates systolic blood pressure, SDP; diastolic blood pressure, LDL; low density cholesterol, HDL, high density cholesterol, WBC; white blood cell count. *P<0.05 vs all other groups.*

Supplemental table 3: RA specific characteristics - *ex vivo* experiments

Characteristic	RA, no anti-TNF (n=16)	RA, anti-TNF (n=20)	P-value
C-reactive protein, mg/L	1.7[1.1-4.3]	2.0[0.7-3.0]	0.789
ESR, mm/H	8[7-18]	6[2-10]	0.042
Disease activity score (DAS28)	2.07[1.4-2.4]	1.80[1.3-2.2]	0.432
Anti-CCP positive (%)	10 (63)	13 (65)	0.619
Rheumatoid factor positive (%)	11 (69)	11 (55)	0.462
Disease duration, years	9.1[5.3-14.0]	16.8[11.8-20.3]	0.008
Anti-TNF	n/a		n/a
- Adalimumab		12	
- Certolizumab		1	
- Etanercept		7	
Disease duration until start anti-TNF, years	1.3[1.0-1.8]	5.3[2.1-9.5]	0.008
Biological withdrawal attempts, yes/no	16/0	20/0	n/a
DMARD			n/a
- Methotrexate	10	17	
- Sulfasalazine	1		
Other Rx			
- Statin	0	1	0.364
- Anti-hypertensive	4	6	0.739

*Values are n or mean ± SD. ESR; erythrocyte sedimentation rate, DAS28 indicates disease activity score based on 28 joints, CCP; cyclic citrulline peptide, DMARD; disease modifying antirheumatic drugs. * P<0.05 vs no biological.*